JPS58203990A - １−アザビシクロ（２，２，２）オクタン誘導体の右旋性異性体 - Google Patents
１−アザビシクロ（２，２，２）オクタン誘導体の右旋性異性体Info
- Publication number
- JPS58203990A JPS58203990A JP58076351A JP7635183A JPS58203990A JP S58203990 A JPS58203990 A JP S58203990A JP 58076351 A JP58076351 A JP 58076351A JP 7635183 A JP7635183 A JP 7635183A JP S58203990 A JPS58203990 A JP S58203990A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- group
- atom
- octane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 14
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 230000001262 anti-secretory effect Effects 0.000 claims description 4
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 208000000718 duodenal ulcer Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000002146 bilateral effect Effects 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 108010079943 Pentagastrin Proteins 0.000 description 2
- 241000736285 Sphagnum Species 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 2
- 229960000444 pentagastrin Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 206010013457 Dissociation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001474791 Proboscis Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960000279 quinupramine Drugs 0.000 description 1
- JCBQCKFFSPGEDY-UHFFFAOYSA-N quinupramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1C(C1)C2CCN1CC2 JCBQCKFFSPGEDY-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8207703 | 1982-05-04 | ||
| FR8207703A FR2526433B1 (fr) | 1982-05-04 | 1982-05-04 | Isomeres dextrogyres de derives de l'aza-1 bicyclo (2,2,2) octane, leur procede de preparation et medicaments les contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS58203990A true JPS58203990A (ja) | 1983-11-28 |
Family
ID=9273691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58076351A Pending JPS58203990A (ja) | 1982-05-04 | 1983-05-02 | １−アザビシクロ（２，２，２）オクタン誘導体の右旋性異性体 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0093643A1 (enExample) |
| JP (1) | JPS58203990A (enExample) |
| AU (1) | AU1419383A (enExample) |
| DK (1) | DK197583A (enExample) |
| ES (1) | ES522063A0 (enExample) |
| FR (1) | FR2526433B1 (enExample) |
| GR (1) | GR72287B (enExample) |
| IL (1) | IL68264A0 (enExample) |
| MA (1) | MA19786A1 (enExample) |
| NO (1) | NO831565L (enExample) |
| PT (1) | PT76487B (enExample) |
| ZA (1) | ZA833137B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0261763B1 (en) * | 1986-06-27 | 1994-02-09 | Beecham Group Plc | Novel bridged bicyclic N-heterocycles |
| GB8615785D0 (en) * | 1986-06-27 | 1986-08-06 | Beecham Group Plc | Compounds |
| IT1251161B (it) * | 1991-08-07 | 1995-05-04 | Derivati ammonio quaternari di (-) e (+)-3-(10 h-fenotiazin-10-ilmetil)-l-azabiciclo (2.2.2.)ottano e composizioni farmaceutiche che li contengono |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1250534A (enExample) * | 1969-03-03 | 1971-10-20 | ||
| FR2052991A1 (en) * | 1969-06-20 | 1971-04-16 | Sogeras | N-(dibenzo (bf) azepines quinuclidines |
| FR2318638A2 (fr) * | 1975-07-25 | 1977-02-18 | Sogeras | Nouveaux derives de la phenothiazine et procede pour leur preparation |
-
1982
- 1982-05-04 FR FR8207703A patent/FR2526433B1/fr not_active Expired
-
1983
- 1983-03-28 IL IL68264A patent/IL68264A0/xx unknown
- 1983-03-31 PT PT76487A patent/PT76487B/pt unknown
- 1983-04-13 GR GR71071A patent/GR72287B/el unknown
- 1983-04-22 EP EP83400801A patent/EP0093643A1/fr not_active Withdrawn
- 1983-04-28 MA MA20006A patent/MA19786A1/fr unknown
- 1983-05-02 JP JP58076351A patent/JPS58203990A/ja active Pending
- 1983-05-03 ES ES522063A patent/ES522063A0/es active Granted
- 1983-05-03 AU AU14193/83A patent/AU1419383A/en not_active Abandoned
- 1983-05-03 NO NO831565A patent/NO831565L/no unknown
- 1983-05-03 DK DK197583A patent/DK197583A/da unknown
- 1983-05-03 ZA ZA833137A patent/ZA833137B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU1419383A (en) | 1983-11-17 |
| ES8407035A1 (es) | 1984-09-01 |
| DK197583A (da) | 1983-11-05 |
| FR2526433A1 (fr) | 1983-11-10 |
| PT76487B (fr) | 1985-12-10 |
| MA19786A1 (fr) | 1983-12-31 |
| EP0093643A1 (fr) | 1983-11-09 |
| GR72287B (enExample) | 1983-10-17 |
| IL68264A0 (en) | 1983-06-15 |
| DK197583D0 (da) | 1983-05-03 |
| FR2526433B1 (fr) | 1985-10-18 |
| ES522063A0 (es) | 1984-09-01 |
| NO831565L (no) | 1983-11-07 |
| ZA833137B (en) | 1984-01-25 |
| PT76487A (fr) | 1983-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6049192B2 (ja) | 新規置換ベンズアミド、その製造方法及びこれを有効成分とする向精神薬 | |
| JPS5921684A (ja) | ３−アミノキヌクリジン誘導体、該誘導体の製法及び該誘導体を用いた治療上用の薬剤 | |
| JPH0366670A (ja) | １，２，３，４―テトラヒドロ―９―アクリジナミンの誘導体 | |
| JPH06510056A (ja) | 新規なイサチンオキシム誘導体類、その製造および使用 | |
| JPS60161970A (ja) | ジベンズアゼピン‐６‐オン化合物 | |
| JPS58203990A (ja) | １−アザビシクロ（２，２，２）オクタン誘導体の右旋性異性体 | |
| JPS5929076B2 (ja) | 化合物 | |
| GB2120662A (en) | New azepinoindoles, their production and pharmaceutical compositions containing them | |
| JPS601300B2 (ja) | 第三アミンの製造方法 | |
| JPS62190184A (ja) | ８α−アクリルアミノエルゴリン、その製造方法および該化合物を含有する医薬組成物 | |
| JPS58162588A (ja) | メキタジンの圧旋性異性体を含有する抗ヒスタミン剤 | |
| JPH0222280A (ja) | スピロキヌクリジン誘導体の光学異性体、それらの製造法、それらからなる薬剤組成物およびそれらを使用した治療法 | |
| US3086972A (en) | Aza-thiaxanthene derivatives | |
| JPS6256478A (ja) | ジアゼピン−１１−オン、その単離法および医薬組成物 | |
| JPH03501389A (ja) | 新規チエニルオキシ‐アルキルアミン誘導体、その製法及びこの化合物を含有する医薬 | |
| JPS585181B2 (ja) | アルアルキルアミンノセイホウ | |
| FR652M (fr) | Nouveau médicament, contenant comme composé actif un dérivé de l’indole ou un de ses sels. | |
| US3351530A (en) | Compositions for producing spasmolytic activity comprising 3-tropanyl-2-phenylacrylate compounds | |
| JPS62158265A (ja) | 光学的活性の２−クロロ−１２−（３−ジメチルアミノ−２−メチルプロピル）−１２Ｈ−ジベンゾ〔ｄ，ｇ〕〔１，３，６〕ジオキサゾシン及びその製造方法 | |
| JPS63141983A (ja) | 置換チエノイミダゾールトルイジン誘導体およびその製法 | |
| JPS624288A (ja) | 新規なジアゼピノン化合物 | |
| US3487153A (en) | Method of treating mental depression | |
| JPS5942385A (ja) | キナゾリノン誘導体 | |
| US3192110A (en) | Therapeutic aryl and thienyl hydroxylamines | |
| RU2015964C1 (ru) | Способ получения замещенных производных амина |